We develop vaccines with our Drosophila S2 platform, ExpreS2, for #covid19, #breastcancer, #malaria, & #flu. #biotech Use https://teapaw.org/t.co/qRjTfDWW92 for Q&A.
Hovedstaden, Danmark
Joined March 2016
- Tweets1.1K
- Following1.7K
- Followers2.4K
- Likes324
Pinned Tweet
Contact us and hear more of our unique ExpreS2 system for #protein proces development and mfg of #antigens #vaccines expres2ionbio.com/contact/
🦟 On #WorldMosquitoDay, we recognise the need to turn science into protection against malaria.
Since 2012, our ExpreS2™ platform has supported @UniofOxford-led blood-stage vaccine programmes RH5.1 and R78C - now licensed to @SerumInstIndia for development. 🌍 teapaw.org/ExpreS2ionB/status/209…
We are excited to be part of the MVC-2G Consortium — a new global partnership created to accelerate #malaria vaccine development, co-led by the
@UniofOxford and the CRNN in Burkina Faso.
Read more paediatrics.ox.ac.uk/news/gl…
#MalariaVaccine #GlobalHealth #vaccines
ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines - read the announcement here: news.cision.com/expres2ion-b… #malaria #malariaresearch #vaccines #vaccinessavelives #SIIPL #ExpreS2 #ExpreS2ion
Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases - read the update here: news.cision.com/expres2ion-b… #malaria #malariaresearch #vaccines #vaccineswork #vaccinessavelives #ClinicalTrials
VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase - read more here news.cision.com/expres2ion-b… #biotech #vaccineswork #vaccinessavelives #nipahvirus
🚀 Promising first-patient results for ExpreS2ion’s therapeutic breast cancer vaccine.
Read more in this company-sponsored article: borsen.dk/sponsoreret/dansk-… (in Danish).
#biotech #innovation #breastcancer #immunotherapy #immunooncology #ES2BC001
ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial - read the news here: news.cision.com/expres2ion-b…
Big 2024 milestones for @ExpreS2ionB:
🚀 CTA approved for Phase I clinical trial
🔬 Progress in preclinical vaccine programs
🤝 Term sheet with @SerumInstIndia
Watch the CEO interview 🎥vimeo.com/1039968561
Exciting 2025 ahead! 🌟 #VaccinesWork #Biotech #Innovation
ExpreS2ion Biotech retweeted
NEW: The results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-MTM) show it is well-tolerated and offers effective protection against the blood-stage of the disease - the first inoculation to do so.
ALT Image of a mosquito standing on human skin, with text overlay announcing the first vaccine against blood-stage malaria, offering effective protection.
Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
news.cision.com/expres2ion-b…
#malaria #malariaresearch #ClinicalTrials #ExpreS2 @UniofOxford
ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer - #breastcancerresearch #breastcancer #vaccinessavelives news.cision.com/expres2ion-b…
ExpreS2ion to present in upcoming investor and scientific events news.cision.com/expres2ion-b… via @cision
ExpreS2ion Biotech will present at the BioStock Life Science Summit, November 21 news.cision.com/expres2ion-b… via @cision
ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002
news.cision.com/expres2ion-b…
#cmv #vaccineswork #vaccinessavelives #ExpreS2 #biotech
📢Listen to a brief Q&A video revolving the recently announced term sheet between @ExpreS2ionB and @SerumInstIndia , as well the newly resolved Reverse Split vimeo.com/1024663058 #VaccinesWork #VaccinesSaveLices #malaria #reversesplit
ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines
news.cision.com/expres2ion-b… #malariaresearch #malariaclinicalvaccine #vaccinessavelives
Brief interview with CEO Bent Frandsen at last week's @BioStock_SWE Stockholm event "Investing in Life Science from Seed to Success" - check it out: youtu.be/Pb6WXQhogMQ
#vaccineswork #vaccinessavelives #breastcancer #breastcancerresearch
ExpreS2ion submits Clinical Trial Application (CTA) to conduct Phase I study of ES2B-C001, an innovative therapeutic breast cancer vaccine news.cision.com/expres2ion-b…
ExpreS2ion announces final outcome of its rights issue news.cision.com/expres2ion-b… via @cision